PCN28 ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2-3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER- A FINNISH PERSPECTIVE
Nov 1, 2007, 00:00
10.1016/S1098-3015(10)65186-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)65186-8/fulltext
Title :
PCN28 ECONOMIC EVALUATION OF SWITCHING TO EXEMESTANE AT 2-3 YEARS VERSUS CONTINUING TAMOXIFEN AS ADJUVANT THERAPY IN EARLY BREAST CANCER- A FINNISH PERSPECTIVE
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)65186-8&doi=10.1016/S1098-3015(10)65186-8
First page :
Section Title :
Open access? :
No
Section Order :
345